Skip to content
‹ Back to IndustriesSciences

Researchers: Viruses Like COVID-19 Can Be Prevented With the Development of a Targeted Nasal Spray Solution

As the world continues to grapple with the ongoing COVID-19 pandemic, scientists are not just working on vaccines and treatments but also on preventive measures that could be simpler yet effective. Imagine a world where a spritz of a nasal spray could help you fight the virus? That notion isn’t just wishful thinking;…

This story was produced through MarketScale. See how Sciences teams put it to work with Executive Thought Leadership.

By Radwa Ewaisha · · Alexandria UniversityCovid-19Dr. Radwa Emad EwaishaFaculty of Pharmacy
Share

Key takeaways

01

As the world continues to grapple with the ongoing COVID-19 pandemic, scientists are not just working on vaccines and treatments but also on preventive measures that could be simpler yet effective.

02

Imagine a world where a spritz of a nasal spray could help you fight the virus?

03

That notion isn’t just wishful thinking;…

Free workspace

Turn your Sciences expertise into content.

Record interviews, organize footage, and write with AI on a free trial of the MarketScale platform for qualifying companies. No demo required, no credit card.

Try it Free

As the world continues to grapple with the ongoing COVID-19 pandemic, scientists are not just working on vaccines and treatments but also on preventive measures that could be simpler yet effective. Imagine a world where a spritz of a nasal spray could help you fight the virus? That notion isn’t just wishful thinking; it’s grounded in intensive research into the anatomy of our respiratory system. Scientists have identified the ports of entry that SARS-CoV-2 exploits to initiate an infection. Once these entry points are known, it becomes possible to develop targeted interventions, specifically targeting the nose. Such a preventive measure could be revolutionary. And not only in combating COVID-19, but also in preparing us for future pandemics of respiratory viruses. 

Detailing more on this exciting frontier is Dr. Radwa Emad Ewaisha, Assistant Professor of Microbiology and Immunology at the Faculty of Pharmacy at Alexandria University. 

She has been teaching and conducting research there since January 2019. She earned her Ph.D. in Cellular and Molecular Biology from Arizona State University. Additionally, she also obtained a Master’s there in the same field. Dr. Ewaisha also completed a Clinical Chemistry Post-PhD Fellowship at the prestigious Mayo Clinic School of Medicine. Prior to her doctorate, she earned a Master’s degree in Pharmaceutical Sciences focusing on Pharmaceutical Microbiology from Alexandria University.

Upon conclusion of recent research exploring nose cells, she added that the development of a nasal solution as a shield against viral infections could be a preventative measure for other possible viral infections. Dr. Ewaisha also stated that this nasal cell research will be groundbreaking for the pharmaceutical industry. 

Dr. Ewaisha’s Thoughts on a Nasal Spray Solution

“These researchers studied cells that line the nose and airway, and they studied the microstructures that are found on these cells, such as cilia and microvilli. They were then able to identify the specific ports of entry in our noses that SARS-CoV-2 uses to start an infection. This means that, in theory, a prophylactic nasal spray can be developed, especially one that can be used following a suspected exposure to the virus, and this has very important implications not only for COVID, but potentially for future pandemics as well. 

“This study has identified targets in these cells that, when inhibited, this can actually prevent respiratory viruses from establishing a stronghold in our nose or throat and spreading the infection to neighboring cells. These targets provide new avenues for pharmaceutical companies to develop and market a prophylactic nasal spray that can abort the infection.”

Your experts belong here

Every story in MarketScale Sciences starts with a company putting its lab directors, applications scientists, and field specialists on the record. Buyers are already reading this topic. The only question is whose experts they find.

Lab and research buyers verify before they trial, and your scientists give them something credible to verify against.

Book DemoSee how it works15 minutes, straight to a calendar.

About the author

Radwa Ewaisha
Radwa EwaishaAssistant Professor of Microbiology and Immunology

Scientist, Pharmacist, YouTuber, Podcaster, Assistant Professor of Microbiology and Immunology who loves to communicate science in different languages.

B2B Weekly

The week in Sciences, and sixteen other industries, every Monday.

Ten stories, one-line takes, five minutes. Free.

Sciences: are you visible to AI?

Before they reach out, Sciences buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free Trial

You just read one Sciences expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your lab directors, applications scientists, and field specialists into the articles, video, and social content Sciences buyers are searching for. Start a free trial and see it with your own people. For qualifying companies, no credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What your free trial includes

Hands-on access to the MarketScale platform
Media requests to your crowd, remote recording, AI writing tools
No demo required. No credit card.
For qualifying companies. Company confirmation required.

More Sciences Insights

Adding Genmab's petosemtamab to Keytruda cut head and neck cancer death risk in half

Adding Genmab's petosemtamab to Keytruda cut head and neck cancer death risk in half

Genmab's petosemtamab, added to Merck's Keytruda, cut the risk of death by 50% in 699 first-line head and neck cancer patients. The trial held regardless of HPV status. Full data will be presented at an upcoming medical meeting.

  • 01In a cancer where median survival runs about 10 to 12 months, adding petosemtamab to Keytruda halved the risk of death at the first interim look.
  • 02The benefit held regardless of HPV status, supporting use in PD-L1-positive patients without separating by HPV status.
  • 03The figure to watch at the full-data presentation is median overall survival in each arm, because the topline release reports only the hazard ratio.

Nov 9, 2026

UCB commits to Veeva Vault CRM for unified engagement

UCB commits to Veeva Vault CRM for unified engagement

UCB has committed to Veeva Vault CRM, which Veeva’s release presents as an agentic CRM platform to drive unified engagement worldwide. UCB and Veeva executives describe it as a stable foundation for UCB’s commercial strategy, while the AI claims, including the Agentic Call Report, come from Veeva’s product description. No go-live date or financial terms were given.

  • 01The executive statements focus on Vault CRM as a foundation. The AI pitch, including the Agentic Call Report, comes from Veeva’s product description.
  • 02Veeva says the Agentic Call Report turns field call records into "Commercial Evidence" about treatment barriers that went unseen before. If it works as described, call reports gain value when analyzed at scale.
  • 03No go-live date or financial terms were disclosed. A go-live date or first-market rollout from UCB would show how quickly a worldwide migration is moving.

Nov 7, 2026

Why ISPE put peptide and oligo facility design in one guide

Why ISPE put peptide and oligo facility design in one guide

ISPE's new Baseline Guide covers oligonucleotide and peptide facility design in one document, says Jim Love of CRB. It pairs a GMP survey of existing plants with a sustainability outlook and a piping safety framework for scale-up, while FDA's oligonucleotide guidances under dockets opened in 2022 and 2024 remain the regulator's own reference.

  • 01Peptide plants inherited API chemistry thinking and oligo plants biotech thinking; ISPE’s guide puts both modalities in one facility document with both inheritances.
  • 02The guide has three parts: a GMP survey of existing oligo and peptide plants, a forecast of how sustainability and scale will change the processes, and a safety framework for connective piping and equipment.
  • 03FDA keeps its own oligonucleotide-specific guidances under dockets opened in 2022 and 2024, so the ISPE guide works as an industry consensus alongside regulation rather than in place of it.

Nov 5, 2026

Explore More Sciences Insights

Read more expert perspectives from across Sciences.

Browse Sciences Hub

About the Expert

Radwa Ewaisha
Radwa Ewaisha

Assistant Professor of Microbiology and Immunology

Scientist, Pharmacist, YouTuber, Podcaster, Assistant Professor of Microbiology and Immunology who loves to communicate science in different languages.

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Sciences and beyond.

Book a Demo

Or call us. No forms required. We pick up. 214-945-2512